Application/Control Number: 09/674,237

Art Unit: 1642

SUPPLEMENTAL EXAMINER'S AMENDMENT

This supplemental Examiner's Amendment replaces previous Examiner's Amendment, which was cancelled.

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with KAREN MAGRI on 04/27/05 and 05/27/05 and 06/15/05.

The application has been amended as follows:

In the specification:

The related application information on the first page, after the title, was updated as follows:

This application claims the benefit under 35 U.S.C. 371 from PCT Application No. PCT/CA99/00375, filed April 27, 1999, the disclosure of which is incorporated by reference herein in its entirety, which claims the benefit of Canadian Application Serial No. 2,230,201, filed April 27, 1998 and U.S. Provisional Application Serial No. 60/118,739, filed February 5, 1999, now abandoned, the disclosures of which are incorporated by reference herein in their entirety.

In the claims:

Claim 1 was amended as follows:

Claim 1 (Amended). An isolated nucleic acid comprising a nucleotide sequence

Application/Control Number: 09/674,237

Art Unit: 1642

selected from the group consisting of:

- (a) a nucleotide sequence encoding the amino acid sequence of SEQ ID NO:3;
- (b) Sequence ID NO:1;
- (c) Sequence ID NO:2; and
- (d) a nucleotide sequence completely complementary to a the sequence of any of (a) to(c).

Claim 7 was amended as follows:

Claim 7 (Amended). An isolated nucleic acid <u>fragment of a nucleotide sequence</u> selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2 and a sequence completely complementary to either of said nucleotide sequences, said <u>fragment</u> consisting of at least 10 consecutive nucleotides of <u>said nucleotide sequence</u> a <u>nucleotide sequence selected from the group consisting of SEQ ID No.1, SEQ ID No. 2 and a sequence completely complementary to either of said nucleic acid sequences.</u>

Any inquiry concerning this communication or earlier communications from the examiner should be directed to MINH-TAM DAVIS whose telephone number is 571-272-0830. The examiner can normally be reached on 8:30AM-5:00PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, JEFFREY SIEW can be reached on 571-272-0787. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Page 4

Application/Control Number: 09/674,237

Art Unit: 1642

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

MINH TAM DAVIS June 16, 2005

SUSAN UNGAR, PH.D. PRIMARY EXAMINER

Juan Jo